Bone marrow transplantation, 2016; doi:10.1038/bmt.2016.123. Authors: Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G Green D J, Bensinger W I, Holmberg L A, Gooley T, Till B G, Budde L E, Pagel J M, Frayo S L, Roden J E, Hedin L, Press O W, Gopal A K et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; City of Hope National Medical Center, Duarte, CA, United States; Fred Hutchinson Cancer Research Center, United States; Fred Hutchinson Cancer Research Center, United States; ...
Hotels near Fred Hutchinson Cancer Research Center, Seattle on TripAdvisor: Find 111,494 traveller reviews, 50,608 candid photos, and prices for 276 hotels near Fred Hutchinson Cancer Research Center in Seattle, WA.
Cytomegalovirus (CMV) infection causes significant morbidity and mortality in the setting of immunodeficiency, including the immune reconstitution phase following allogeneic stem cell transplantation (SCT). We assessed CMV-specific CD4(+) and CD8(+) T-cell responses in 87 HLA-A*0201-positive (A2+) and/or B*0702-positive (B7+) allogeneic stem cell transplant recipients using HLA-peptide tetramer staining and cytokine flow cytometry (CFC) to examine the association of CMV-specific immune reconstitution and CMV antigenemia following SCT. Strong CMV-specific T-cell responses recovered in most subjects (77 of 87, 88%) after SCT. Frequencies of CMV-specific CD8(+) T cells were significantly higher in those subjects who experienced early antigenemia relative to those who did not (2.2% vs 0.33%, P =.0002), as were frequencies of CMV-specific CD4(+) T cells (1.71% vs 0.75%, P =.002). Frequencies of CMV-specific CD8(+) T cells were also higher in subjects experiencing late antigenemia (2.4% vs 0.57%). When we
One of the worlds leading bone marrow transplant experts is recommending a significant change to current transplant practice for patients who need marrow or adult stem cells from an unrelated donor to treat hematologic malignancies. Fred Appelbaum, M.D., director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, asserts that bone marrow - not circulating, peripheral blood, which is the current norm - should be the source for unrelated donor adult stem cells for most patients who require a transplant. The reason: because there is less incidence of chronic graft-versus-host disease (GVHD), which can be a debilitating side effect of transplantation.
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells - while the immune cells are still inside the body.. In a proof-of-principle study to be published April 17 [2017] in Nature Nanotechnology, the team showed that nanoparticle-programmed immune cells, known as T cells, can rapidly clear or slow the progression of leukemia in a mouse model.. Our technology is the first that we know of to quickly program tumor-recognizing capabilities into T cells without extracting them for laboratory manipulation, said Fred Hutchs Dr. Matthias Stephan, the studys senior author. The reprogrammed cells begin to work within 24 to 48 hours and continue to produce these receptors for weeks. This suggests that our technology has the potential to allow the immune system to quickly mount a strong enough response to destroy cancerous cells before the disease becomes ...
The Avgousti lab at the Fred Hutchinson Cancer Research Center has an opening for a postdoctoral fellow. Our laboratory uses a multidisciplinary approach to investigate the mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential. Our goal is to advance basic understanding of viral manipulation of chromatin and uncover new aspects of chromatin biology.. Much like the cellular genome, viral genomes are compacted in virus particles with small basic molecules to maximize space and be poised for gene expression. Some DNA viruses use cellular histone proteins to compact their genomes whereas others use small basic molecules. Adenoviruses encode their own histone-like protein, called protein VII, that forms a beads on a string assembly with the viral genome. By examining protein VII in host chromatin, we discovered that protein VII ...
Fred Hutchinson Cancer Research Center is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It
Market your lab products and lab equipment to the life science professionals at the Fred Hutchinson Cancer Research Center in Seattle, WA in the upcoming BioResearch Product Faire™ Event.
Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs ...
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM. 2013. Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract ...
Hill, GR, Ferrara, JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
Bone marrow transplantation, or allogeneic hematopoietic stem cell transplant (HCT), is the only curative therapy for many patients with leukemia. Certain immune cells, called T cells, contained in the donor HCT graft can cause a graft versus leukemia (GVL) effect which eliminates leukemic cells. Unfortunately, there are also donor T cells in the HCT graft that can cause a condition called graft versus host disease (GVHD). GVHD is a life-threatening immune response that remains the major barrier to the success of transplantation. Dr. ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
The purpose of the study is to examine the safety and effectiveness of a reduced intensity conditioning regimen and allogeneic bone marrow transplant for people with systemic sclerosis. In an allogeneic bone marrow transplant procedure, bone marrow is taken from a healthy donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who is a complete tissue type match.. Participants will receive the chemotherapy and low dose radiation conditioning regimen consisting of the following: Fludarabine will be given intravenously for 5 days. Cyclophosphamide will be given intravenously on the first and second day. After completing the fludarabine and cyclophosphamide, patients will receive a single low dose of total body irradiation. The next day, patients will receive the allogeneic bone marrow transplant. On the third and fourth day after the transplant, patients will receive high dose intravenous cyclophosphamide. This is given to help prevent two ...
平成23年4月 岡山大学病院講師(輸血部). 【一言】丁寧で安定感のある診療を心がけています。. 【研究テーマ】移植後肺合併症、ドナーリンパ球輸注によるGVL効果. 【主な業績】. ● Nishie M , Fujii N, Mimura Y , Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka KI, Kondo E, Maeda Y, Tanimoto M. Vigorous inflammatory responses in non-infectious pulmonary complication induced by donor lymphocyte infusion. Transfusion. 2015 (in press). ● Asano T, Fujii N, Niiya D, Nishimori H, Fujii K, Matsuoka K, Ichimura K, Hamada T, Kondo E, Maeda Y, Tanimoto Y, Shinagawa K, Tanimoto M. Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. Springerplus. 2014 Jan 2;3:3. ● Fujii N, Nakase K, Asakura S, Matsuo K, Nawa Y, Sunami K, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Shinagawa K, Hara M, Tanimoto M ...
HOPA supports pharmacy practitioners and seeks to promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer
Mice given short courses of anti-CD4 and anti-CD8 monoclonal antibodies became tolerant of allogeneic skin grafted at the same time. Tolerance could be obtained without T cell depletion across multiple minor antigen mismatches, both in naive and primed animals, demonstrating that peripheral T cells could be tolerized, even if they had been previously activated. Where donor and recipient were incompatible across the whole major histocompatibility complex, specific tolerance could be achieved by using a combination of depleting followed by non-depleting antibodies, where each alone was unsuccessful. Although mice clearly tolerated their original skin grafts, we observed in some strain combinations that a second fresh, but genotypically identical graft, was slowly rejected. Such mice also possessed T cells which could proliferate to donor-type stimulator cells in vitro. Whatever the mechanisms, we have demonstrated that operational transplantation tolerance can be achieved with simple, non-toxic antibody
Graft-versus-host disease remains a major cause of transplant-related mortality. Interleukin-2 plus sirolimus synergistically reduces acute graft-versus-host disease in rodents and promotes regulatory T-cells. This phase II trial tested the hypothesis that interleukin-2 would facilitate STAT5 phosphorylation in donor T-cells, expand regulatory T-cells, and ameliorate graft-versus-host disease. Between 4/16/2014-12/19/2015, 20 patients received interleukin-2 (200,000IU/m2 thrice weekly, days 0 to +90) with sirolimus (5-14ng/ml) and tacrolimus (3-7ng/ml) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation. The study was designed to capture an increase in regulatory T-cells from 16.0% to ,23.2% at day +30. Interleukin-2/sirolimus/tacrolimus significantly increased regulatory T-cells at day +30 compared to our published data with sirolimus/tacrolimus (23.8% versus 16.0%, P=0.0016; 0.052 k/ul versus 0.037 k/ul, P=0.0163), achieving the primary study endpoint. However, ...
H.Joachim Deeg from Fred Hutchinson Cancer Research CenterClinical ResearchFull Member is a speaker at Eurocancersummit-2015 conference | Conferenceseries Ltd
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma. T2 - A CIBMTR analysis. AU - Epperla, Narendranath. AU - Ahn, Kwang W.. AU - Litovich, Carlos. AU - Ahmed, Sairah. AU - Battiwalla, Minoo. AU - Cohen, Jonathon B.. AU - Dahi, Parastoo. AU - Farhadfar, Nosha. AU - Farooq, Umar. AU - Freytes, Cesar O.. AU - Ghosh, Nilanjan. AU - Haverkos, Bradley. AU - Herrera, Alex. AU - Hertzberg, Mark. AU - Hildebrandt, Gerhard. AU - Inwards, David. AU - Kharfan-Dabaja, Mohamed A.. AU - Khimani, Farhad. AU - Lazarus, Hillard. AU - Lazaryan, Aleksandr. AU - Lekakis, Lazaros. AU - Murthy, Hemant. AU - Nathan, Sunita. AU - Nishihori, Taiga. AU - Pawarode, Attaphol. AU - Prestidge, Tim. AU - Ramakrishnan, Praveen. AU - Rezvani, Andrew R.. AU - Romee, Rizwan. AU - Shah, Nirav N.. AU - Sureda, Ana. AU - Fenske, Timothy S.. AU - Hamadani, Mehdi. PY - 2019/1/10. Y1 - ...
SEATTLE - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.. Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize ...
TY - JOUR. T1 - Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia. T2 - Results of a prospective observational study. AU - Schetelig, Johannes. AU - Hoek, Jennifer. AU - Stilgenbauer, Stephan. AU - Middeke, Jan Moritz. AU - Andersen, Niels Smedegaard. AU - Fox, Christopher P.. AU - Lenhoff, Stig. AU - Volin, Liisa. AU - Shimoni, Avichai. AU - Schroyens, Wilfried. AU - van Gelder, Michel. AU - Bunjes, Donald. AU - van Biezen, Anja. AU - Baldauf, Henning. AU - de Wreede, Liesbeth C.. AU - Tournilhac, Olivier. AU - Kroeger, Nicolaus. AU - Yakoub-Agha, Ibrahim. AU - Dreger, Peter. PY - 2020/8/16. Y1 - 2020/8/16. KW - FOLLOW-UP. KW - RETROSPECTIVE ANALYSIS. KW - EUROPEAN-SOCIETY. KW - CLL. KW - BLOOD. U2 - 10.1038/s41409-020-01013-y. DO - 10.1038/s41409-020-01013-y. M3 - Letter. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. ER - ...
Fred Hutchs Business Development and Industry Relations manages and commercializes our intellectual property assets. Partners are vital to the commercialization process; our goal is to work as efficiently and collaboratively as possible to achieve shared goals.
Bart L. Scott, MD, MS, is Assistant Professor at the University of Washington Medical Center and Assistant Member at the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received his medical degree from the University of South Alabama and his masters of Science in Epidemiology from the University of Washington, Seattle. He completed his residency in Internal Medicine at Johns Hopkins Hospital in Baltimore, MD, where he also served as Assistant Chief of Services. His medical oncology fellowship was completed at Fred Hutchinson Cancer Research Center. Dr.
Blood, 1996; 88 (9) doi:. Authors: Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E Nash R A, Piñeiro L A, Storb R, Deeg H J, Fitzsimmons W E, Furlong T, Hansen J A, Gooley T, Maher R M, Martin P, McSweeney P A, Sullivan K M, Anasetti C, Fay J W et al.(9) Affiliation: Fred Hutchinson Cancer Research Center, United States Sample size: 25 Abstract: The safety and potential efficacy of FK506 in combination with a short course of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow transplantation from HLA-matched unrelated donors was evaluated in a single-arm Phase II study conducted at two centers. Forty-three patients, 15 to 54 (median 41) years of age, were transplanted for hematologic malignancies. Thirty-seven of 43 evaluable patients had evidence of sustained marrow engraftment. Five patients died before day 17 after transplantation. The median time to an absolute neutrophil count of > 0.5 x 10(5)/L was 21 (range, 14 to 30) days. ...
Non-competitive 5K and one mile run/walk in support of research and awareness for multiple myeloma the second most common type of blood cancer.
Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is director of the pediatric hematology-oncology fellowship at the University of Washington.. Julie R. Park, MD, is attending physician at Seattle Childrens Hospital, professor in pediatrics at the University of Washington School of Medicine and associate in the Clinical Research Division at Fred Hutchinson Cancer Research Center (FHCRC). She is medical director of Immunotherapy Coordinating Center within the Immunotherapy Integration Hub and is medical director of the Cancer and Blood Disorders Advanced Therapeutics clinical research program.. Dr. Parks primary research focus has been investigating novel therapies for the treatment of refractory and recurrent cancers with a specific focus on high-risk neuroblastoma, a rare but aggressive form of ...
TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
TY - JOUR. T1 - Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. T2 - a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. AU - Ohashi, Kazuteru. AU - Nagamura-Inoue, Tokiko. AU - Nagamura, Fumitaka. AU - Tojo, Arinobu. AU - Miyamura, Kouichi. AU - Mori, Takehiko. AU - Kurokawa, Mineo. AU - Taniguchi, Shuichi. AU - Ishikawa, Jun. AU - Morishima, Yasuo. AU - Atsuta, Yoshiko. AU - Sakamaki, Hisashi. PY - 2014/9/1. Y1 - 2014/9/1. N2 - We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic ...
TY - JOUR. T1 - Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. AU - Balassa, Katalin. AU - Krahling, Tunde. AU - Remenyi, Peter. AU - Batai, Arpad. AU - Bors, Andras. AU - Kiss, Katalin Piroska. AU - Torbagyi, Eva. AU - Gopcsa, Laszlo. AU - Lengyel, Lilla. AU - Barta, Aniko. AU - Varga, Gergely. AU - Tordai, A.. AU - Masszi, T.. AU - Andrikovics, H.. PY - 2016/7/7. Y1 - 2016/7/7. N2 - Several genetic polymorphisms have been implicated to affect the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The role of cytokines in acute graft-versus-host disease (aGvHD) is well established and many of the involved cytokines signal through the Janus kinase (JAK) pathways. In this study, we assessed the association of recipient and donor JAK2 46/1 haplotypes and allo-HSCT outcome in a cohort of 124 acute myeloid leukemia patients. Both, recipient and donor 46/1 haplotypes ...
TY - JOUR. T1 - Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. AU - Anderson, Larry D.. AU - Savary, Cherylyn A.. AU - Mullen, Craig A.. PY - 2000/4/1. Y1 - 2000/4/1. N2 - Allogeneic bone marrow transplantation (BMT) induces 2 closely associated immune responses: graft-versus-tumor (GVT) activity and graft- versus-host disease (GVHD). We have previously shown that pretransplant immunization of allogeneic BMT donors with a recipient-derived tumor cell vaccine increases both GVT activity and lethal GVHD because of the priming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor vaccine cells. The work reported here tested the hypothesis that tumor cell vaccination after BMT would produce an increase in GVT activity without exacerbating GVHD. C3H.SW donor bone marrow and splenocytes were transplanted into major histocompatibility ...
BACKGROUND & OBJECTIVE: Patients with refractory or relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation had a poor prognosis with high death rate due to relapse or transplant-related mortality (TRM). The purpose of this paper was to clarify the role of inducing acute graft-versus-host disease (aGVHD) during transplantation in preventing relapse.. METHODS: Thirty adult patients with refractory or relapsed leukemia were acute lymphoblastic leukemia (n=16), acute myelogenous leukemia (n=10), and acute mixed leukemia (n=4). They were in first complete remission (n=4), second complete remission (n=9), partly remission (n=12), and non-response (n=5) at the time of transplantation. Patients underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-identical siblings (n=21), mismatched siblings donors (n=3), and allogeneic bone marrow transplantation (n=5) or allo-PBSCT (n=1) from unrelated HLA matched donors. All patients received myeloablative ...
TY - JOUR. T1 - Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. AU - Fujii, Nobuharu. AU - Ikeda, Kazuma. AU - Koyama, Motoko. AU - Aoyama, Kazutoshi. AU - Masunari, Taro. AU - Kondo, Eisei. AU - Matsuzaki, Takashi. AU - Mizobuchi, Satoshi. AU - Hiraki, Akio. AU - Teshima, Takanori. AU - Shinagawa, Katsuji. AU - Ishimaru, Fumihiko. AU - Tanimoto, Mitsune. PY - 2006/6/1. Y1 - 2006/6/1. N2 - The calcineurin inhibitors (CIs) cyclosporine A and tacrolimus are essential for graft-versus-host disease prophylaxis but are associated with adverse effects, including neurotoxicity. We report a case of irreversible CI-induced neuropathic pain following allogeneic hematopoietic stem cell transplantation. The patient developed dysesthesia, electric shock-like pain, and severe itching followed by intractable analgesic-resistant pain in the lower extremities. There were no abnormal radiographic findings, and there was no improvement with a ...
Purpose of reviewCytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is no
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
The University of Washington and Fred Hutchinson Cancer Research Center have been awarded a four-year $4.8 million contract by the National Human Genome Research Institute (NHGRI) of the National Inst...
Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups, and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at three years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively ...
TY - JOUR. T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. AU - Lupo-Stanghellini, Maria Teresa. AU - Provasi, Elena. AU - Bondanza, Attilio. AU - Ciceri, Fabio. AU - Bordignon, Claudio. AU - Bonini, Chiara. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most ...
TY - JOUR. T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. AU - Saburi, Masuho. AU - Kohashi, Sumiko. AU - Kato, Jun. AU - Koda, Yuya. AU - Sakurai, Masatoshi. AU - Toyama, Takaaki. AU - Kikuchi, Taku. AU - Karigane, Daiki. AU - Yuda, Sayako. AU - Yamane, Yusuke. AU - Hashida, Risa. AU - Abe, Ryohei. AU - Nakazato, Tomonori. AU - Hirahashi, Junichi. AU - Ogata, Masao. AU - Okamoto, Shinichiro. AU - Mori, Takehiko. PY - 2017/5/17. Y1 - 2017/5/17. N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT ...
EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022 For correspondence: Elena Vladislavovna Morozova, MD, PhD, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022; e-mail: [email protected] For citation: Morozova EV, Vlasova YuYu, Barabanshchikova MV, et al. Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors. Clinical oncohematology. 2020;13(2):193-8 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-193-198 ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a radical method of chronic myeloid leukemia (CML) treatment. In the 1990s CML became the most frequent
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk cytogenetics ...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
TY - JOUR. T1 - Vitamin D level after allogeneic hematopoietic stem cell transplant. AU - Sproat, Lisa. AU - Bolwell, Brian. AU - Rybicki, Lisa. AU - Dean, Robert. AU - Sobecks, Ronald. AU - Pohlman, Brad. AU - Andresen, Steven. AU - Sweetenham, John. AU - Copelan, Edward. AU - Kalaycio, Matt. PY - 2011/7. Y1 - 2011/7. N2 - Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/osteopenia. We therefore studied the incidence of ...
The purpose of this study is to evaluate the outcome of imatinib combined with reduced-intensity allogeneic hematopoietic stem cell transplantation versus
PubMed journal article: Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Download Prime PubMed App to iPhone, iPad, or Android
Introduction. Cyclosporin (CSA) is commonly used as graft vs host disease (GvHD) prophylaxis in allogeneic haematopoietic stem cell transplant (alloHSCT) recipients. The usual IV dose is 3mg/kg and the recommended oral dose at switching is 3mg/kg BD in the pre-posaconazole era (Inoue et al. 2014). Posaconazole is now commonly used as antifungal prophylaxis in this context; it increases CSA levels through inhibition of the cytochrome involved in CSA metabolism (Sánchez-Ortega et al. 2012). We evaluated CSA-related toxicity after switch from IV to oral CSA in alloHSCT recipients receiving posaconazole with the aim of defining the optimal weight based oral dose.. Methods. A retrospective audit was performed of adult alloHSCT patients between October 2015 and October 2017 who received IV and then oral CSA together with posaconazole prophylaxis. Posaconazole was commenced during conditioning and continued at 300mg IV or oral daily according to gastrointestinal tolerance; patients with levels below ...
These experiments explored mechanisms of control of acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation using a murine model of MHC-matched, minor histocompatibility antigen mismatched transplantation. The central hypothesis examined was that addition of active vaccination against leukemia cells would substantially increase the effectiveness of allogeneic donor lymphocyte infusion against ALL present in the host after transplant. While vaccination did increase the magnitude of type I T cell responses against leukemia cells associated with donor lymphocyte infusion, it did not lead to substantial improvement in long term survival. Analysis of immunological mechanisms of leukemia progression demonstrated that the failure of vaccination was not due to antigen loss in leukemia cells. However, analysis of survival provided surprising findings that, in addition to very modest type I T cell responses, a B cell response that produced antibodies that bind leukemia ...
Yi-Bin Chen, Massachusetts General Hospital, Boston, US, and colleagues explored the potential benefits of coadministration of vedolizumab with standard GvHD prophylaxis in a phase Ib study
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant diseases, as well as a small proportion of non-malignant disorders. The treatment before the HSCT (called conditioning) can be either myeloablative (MAC) or given with reduced intensity (RIC). MAC is associated with high toxicity due to high doses of chemotherapy with or without total body irradiation (TBI), and is used in both autologous and allogeneic HSCT. In autologous HSCT the patient is the donor, and in allogeneic HSCT the donor is a sibling or an unrelated donor. RIC regimens are associated with reduced toxicity and are only for patients undergoing allogeneic HSCT. Both autologous and allogeneic HSCT have a strong effect on the patients health-related quality of life (HRQL). The two studies in this thesis were initiated when RIC was introduced at a hematological department in south-east Sweden in 2001. The overall purpose was to evaluate HRQL in patients undergoing HSCT. The studies ...
TY - JOUR. T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. AU - Muramatsu, Hideki. AU - Sakaguchi, Hirotoshi. AU - Taga, Takashi. AU - Tabuchi, Ken. AU - Adachi, Souichi. AU - Inoue, Masami. AU - Kitoh, Toshiyuki. AU - Suminoe, Aiko. AU - Yabe, Hiromasa. AU - Azuma, Eichi. AU - Shioda, Yoko. AU - Ogawa, Atsushi. AU - Kinoshita, Akitoshi. AU - Kigasawa, Hisato. AU - Osugi, Yuko. AU - Koike, Kazutoshi. AU - Kawa, Keisei. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Kudo, Kazuko. PY - 2014/5. Y1 - 2014/5. N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
指紋 深入研究「Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia」主題。共同形成了獨特的指紋。 ...
Rabbit polyclonal to Dynamin-1.Dynamins represent one of the subfamilies of GTP-binding proteins.These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain.Dynamins are associated with microtubules.. black individuals from the prior research had been lost to check out up. Three brand-new alloHSCT recipients had been enrolled. We contacted five entitled alloHSCT recipients to sign up the three brand-new alloHSCT SDZ 220-581 Ammonium salt individuals. HSCT and matched-control individuals had been enrolled more than a 15-month period. The matched-control and alloHSCT characteristics are summarized in Desk 1. All individuals had been Caucasian. AlloHSCT was connected with postponed maturation. Elevation Z-scores had been markedly low in alloHSCT individuals while BMI Z-scores didnt differ considerably. AlloHSCT sitting elevation relative to elevation was considerably lower in comparison to handles (p ...
Hematopoietic Cell Transplantation, 2nd ed. Blackwell Science, London, 1999, pp. 823-834. 3. Forman SJ, Krance RA, ODonnell MR, et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors. Transplantation 1987;43:650-653. 4. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. 59. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998;12 (suppl. 1):S25-S29. Chapter 2 / Allogeneic BMT for AML 27 60. Fefer A. Graft-versus-tumor responses. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Blackwell ...
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant
Background: Renal dysfunction after allogeneic hematopoietic stem cell transplantation (HSCT) has been increasingly reported. However, there are few reports on the changes of the estimated glomerular filtration rate (eGFR) in long-term survivors after allogeneic HSCT. Patients and methods: The medical records at Seoul St. Marys Hospital in Korea were reviewed to identify all adult (, 18 years of age) patients who had undergone high-dose chemotherapy and allogeneic HSCT between January 2001 and December 2005. Among these patients, those with , 5 years of follow-up and relapse within 5 years after HSCT were excluded. 85 patients were enrolled. Results: The mean follow-up was 76.0 +/- 13.5 months. The eGFR recorded 3 months after HSCT was significantly decreased compared with the eGFR recorded before HSCT. Subsequently, early decreased eGFR was maintained during the 60 months after HSCT. Multivariate analysis showed that acute kidney injury (AKI) during HSCT, hypertension (HTN) and eGFR before ...
Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.
Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host DiseaseConference abstracts...
Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related disorders - Part I ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - http://www.scopus.com/inward/record.url?scp=0030979295&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030979295&partnerID=8YFLogxK. U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
Xu, L.,Zhu, H. L.,Hu, J. D.,et al. SUPERIORITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TO NILOTINIB & DASATINIB FOR ADULT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN THE ACCELERATED PHASE[J]. HAEMATOLOGICA,2015,suppl.1:434-434 ...
Full text of Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation 1st ed. (2013) Gerard Socie and B.R. Blazar is part of the ScienceDirect eBook Collection. For USC users only. Requires USC network connection.. ...
This retrospective report compared the results of graft source on outcome after allogeneic stem cell transplantation (allo-SCT) in patients with hematologic malignancies receiving a reduced intensity conditioning (RIC) regimen. A total of 152 patients received either a RIC allo-SCT using a 9/10 mismatched unrelated donor (MisMUD, n=42) or a double unrelated umbilical cord blood (dUCB, n=110) graft. With a median follow-up of 30.3 months, the cumulative incidence of non-relapse mortality was 26% in the dUCB group versus 24% in the MisMUD group (P=0.95). Grade 3-4 acute graft-versus-host disease (GVHD) incidence was 19.7% in the dUCB group versus 21.4% in the MisMUD group (P=0.83). The cumulative incidence of extensive chronic GVHD at 2 years was 6.4% in the dUCB group versus 21.4% in the MisMUD group (P=0.02). The Kaplan-Meier estimate of overall survival at 2 years was comparable between both groups (52.3% (95% confidence interval (CI), 42.1-61.5%) in the dUCB group versus 47.9% (95% CI, 31.6-62.4%) in